TOP STORIES

• BUSINESS Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
  April 12, 2019

• BUSINESS Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
  April 12, 2019

• BUSINESS Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
  April 11, 2019

• BUSINESS Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
  April 10, 2019

• ORGANIZATION Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
  April 9, 2019

• REGULATORY Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
  April 9, 2019

• BUSINESS Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
  April 9, 2019

• BUSINESS Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
  April 8, 2019

• REGULATORY Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
  April 8, 2019

• INTERVIEW With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
  April 5, 2019

• BUSINESS Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
  April 4, 2019

• BUSINESS Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
  April 4, 2019

• INTERVIEW Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
  April 3, 2019

• COMMENTARY Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
  April 2, 2019

• REGULATORY MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
  April 1, 2019

• BUSINESS Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
  April 1, 2019

• INTERVIEW Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
  March 29, 2019

• BUSINESS Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
  March 29, 2019

• REGULATORY Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
  March 28, 2019

• REGULATORY National Cancer Center’s Fujiwara Named New PMDA Chief
  March 27, 2019

ページ

• « 先頭
• ‹ Prev
• …
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• …
• Next ›
• 最終 »